ストックスクリーナーアプリを入手
91.88
1.47%
-1.37
Corcept Therapeutics Inc (CORT) 最新ニュース
Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup - ChartMill
Fed. Circ. Won't Rethink Corcept Patent Loss In Teva Case - Law360
Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors - Seeking Alpha
Corcept Therapeutics : CORT - 24/7 Wall St.
CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits
Form 4 Corcept Therapeutics Incorporated For: 8 July By Investing.com - Investing.com Nigeria
Corcept (NASDAQ: CORT) CBO reports 600-share stock gift and holdings - Stock Titan
Corcept Therapeutics CDO William Guyer sells $1.86m in stock - Investing.com
Insider at Corcept (NASDAQ: CORT) sells shares after option exercise - Stock Titan
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
Form 144 CORCEPT THERAPEUTICS INC For: 7 July By Investing.com - Investing.com Nigeria
William Guyer to sell 20,000 CORT shares (NASDAQ: CORT) via option exercise - Stock Titan
CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits
Corcept Therapeutics highlights its endocrine focus as investors watch CORT stock - AD HOC NEWS
CORT News | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept (CORT) executive sells 25K shares after exercising options - Stock Titan
CORTCorcept Therapeutics Inc Options - Finviz
Corcept Therapeutics stock hits 52-week high at 91.1 USD By Investing.com - Investing.com Canada
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report - Sahm
Price to sales forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Price to book forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Enterprise value to revenue forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Price to earnings forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Corcept sinks after FDA rejects drug to treat hypertension - MSN
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Defensive Index - marketscreener.com
Corcept gives FDA new relacorilant data in resubmitted application - Cushing's Disease News
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - PR Newswire
Number of shareholders of Corcept Therapeutics Incorporated. – BX:HTD - TradingView
Corcept Therapeutics Incorporated. Actuals & Estimates (NASDAQ:CORT) - TradingView
HTD Forecast — Price Target — Prediction for 2027 - TradingView
Corcept Therapeutics Inc (CORT) Institutional Confidence - TradingKey
Corcept Therapeutics Inc (CORT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corcept Therapeutics Inc (CORT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Corcept Therapeutics Inc (CORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Corcept Therapeutics Inc (CORT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corcept Therapeutics Inc (CORT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trust linked to Corcept (NASDAQ: CORT) director sells 10,000 shares in plan - Stock Titan
Corcept (CORT) director’s entities report 20K-share sale and large holdings - Stock Titan
Wolfe Research Upgrades Corcept Therapeutics (CORT) to Peer Perf - GuruFocus
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Corcept Therapeutics Inc (CORT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome - Business Wire
Corcept Therapeutics Inc (CORT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corcept Therapeutics (CORT) Resubmits NDA for Relacorilant with New Data - GuruFocus
Corcept Therapeutics (CORT) Resubmits Drug Application for Cushi - GuruFocus
Corcept Therapeutics (CORT) resubmits FDA NDA for relacorilant in Cushing’s syndrome - Stock Titan
2.64%
大文字化:
|
ボリューム (24 時間):